PATENT CLAIM ANALYSIS

Application Number: 15975733
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-11
Patent Classification: ["424", "456000"]

Abstract:
Disclosed herein is, among other things, a soft gel vaginal pharmaceutical composition and dosage form containing solubilized estradiol for the treatment of vulvovaginal atrophy (VVA) and female sexual dysfunction (FSD).

Claim (Index 14):
A method of treating moderate to severe dyspareunia, comprising vaginally administering to a subject in need thereof a liquid pharmaceutical composition comprising estradiol at a dosage of 4 mcg once daily for two weeks, then twice weekly thereafter and increasing the dosage of estradiol if the subject does not exhibit an improvement in the moderate to severe dyspareunia.

Metadata:
- Claim Count in Document: 42.0
- Percentile: 93.0
- Lexical Diversity: 1.12121
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15975723', '15893546', '15372385', '15893542', '15893550']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7991608879452742
- 35 USC 102 Novelty (BERT): 0.6492241320616672
- Combined Prediction Score: 0.7841672123569136
- Mean Citation Score: 594.3824280000001
- Max Citation Score: 696.49207
- Similarity Product: 594.2360456905318

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test